Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury

Traumatic Brain Injury (TBI) is a significant contributor to disability across the world. TBIs vary in severity, and most cases are designated mild TBI (mTBI), involving only brief loss of consciousness and no intracranial findings on imaging. Despite this categorization, many persons continue to re...

Full description

Saved in:
Bibliographic Details
Main Authors: Siddharth Khasnavis, Timothy Belliveau, Amy Arnsten, Arman Fesharaki-Zadeh
Format: Article
Language:English
Published: Mary Ann Liebert 2024-11-01
Series:Neurotrauma Reports
Subjects:
Online Access:https://www.liebertpub.com/doi/10.1089/neur.2023.0124
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850030858712383488
author Siddharth Khasnavis
Timothy Belliveau
Amy Arnsten
Arman Fesharaki-Zadeh
author_facet Siddharth Khasnavis
Timothy Belliveau
Amy Arnsten
Arman Fesharaki-Zadeh
author_sort Siddharth Khasnavis
collection DOAJ
description Traumatic Brain Injury (TBI) is a significant contributor to disability across the world. TBIs vary in severity, and most cases are designated mild TBI (mTBI), involving only brief loss of consciousness and no intracranial findings on imaging. Despite this categorization, many persons continue to report persistent cognitive changes in the months to years after injury, with particular impairment in the cognitive and executive functions of the pre-frontal cortex. For these persons, there are no currently approved medications, and treatment is limited to symptom management and cognitive or behavioral therapy. The current case studies explored the use of the alpha-2A adrenoreceptor agonist, guanfacine, combined with the antioxidant, N-acetylcysteine (NAC), in the treatment of post-TBI cognitive symptoms, based on guanfacine's ability to strengthen pre-frontal cortical function, and the open-label use of NAC in treating TBI. Two persons from our TBI clinic were treated with this combined regimen, with neuropsychological testing performed pre- and post-treatment. Guanfacine + NAC improved attention, processing speed, memory, and executive functioning with minimal side effects in both persons. These results encourage future placebo-controlled trials to more firmly establish the efficacy of guanfacine and NAC for the treatment of cognitive deficits caused by TBI.
format Article
id doaj-art-eacf0d2c9c474e13a2a032ce8e9d0e5e
institution DOAJ
issn 2689-288X
language English
publishDate 2024-11-01
publisher Mary Ann Liebert
record_format Article
series Neurotrauma Reports
spelling doaj-art-eacf0d2c9c474e13a2a032ce8e9d0e5e2025-08-20T02:59:07ZengMary Ann LiebertNeurotrauma Reports2689-288X2024-11-015122623110.1089/neur.2023.0124Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain InjurySiddharth Khasnavis0Timothy Belliveau1Amy Arnsten2Arman Fesharaki-Zadeh3Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.Department of Neurology, Yale School of Medicine, New Haven, Connecticut, USA.Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.Traumatic Brain Injury (TBI) is a significant contributor to disability across the world. TBIs vary in severity, and most cases are designated mild TBI (mTBI), involving only brief loss of consciousness and no intracranial findings on imaging. Despite this categorization, many persons continue to report persistent cognitive changes in the months to years after injury, with particular impairment in the cognitive and executive functions of the pre-frontal cortex. For these persons, there are no currently approved medications, and treatment is limited to symptom management and cognitive or behavioral therapy. The current case studies explored the use of the alpha-2A adrenoreceptor agonist, guanfacine, combined with the antioxidant, N-acetylcysteine (NAC), in the treatment of post-TBI cognitive symptoms, based on guanfacine's ability to strengthen pre-frontal cortical function, and the open-label use of NAC in treating TBI. Two persons from our TBI clinic were treated with this combined regimen, with neuropsychological testing performed pre- and post-treatment. Guanfacine + NAC improved attention, processing speed, memory, and executive functioning with minimal side effects in both persons. These results encourage future placebo-controlled trials to more firmly establish the efficacy of guanfacine and NAC for the treatment of cognitive deficits caused by TBI.https://www.liebertpub.com/doi/10.1089/neur.2023.0124cognitive symptomsguanfacineN-acetylcysteinetraumatic brain injury
spellingShingle Siddharth Khasnavis
Timothy Belliveau
Amy Arnsten
Arman Fesharaki-Zadeh
Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury
Neurotrauma Reports
cognitive symptoms
guanfacine
N-acetylcysteine
traumatic brain injury
title Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury
title_full Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury
title_fullStr Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury
title_full_unstemmed Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury
title_short Combined Use of Guanfacine and N-Acetylcysteine for the Treatment of Cognitive Deficits After Traumatic Brain Injury
title_sort combined use of guanfacine and n acetylcysteine for the treatment of cognitive deficits after traumatic brain injury
topic cognitive symptoms
guanfacine
N-acetylcysteine
traumatic brain injury
url https://www.liebertpub.com/doi/10.1089/neur.2023.0124
work_keys_str_mv AT siddharthkhasnavis combineduseofguanfacineandnacetylcysteineforthetreatmentofcognitivedeficitsaftertraumaticbraininjury
AT timothybelliveau combineduseofguanfacineandnacetylcysteineforthetreatmentofcognitivedeficitsaftertraumaticbraininjury
AT amyarnsten combineduseofguanfacineandnacetylcysteineforthetreatmentofcognitivedeficitsaftertraumaticbraininjury
AT armanfesharakizadeh combineduseofguanfacineandnacetylcysteineforthetreatmentofcognitivedeficitsaftertraumaticbraininjury